Skip to Content
Merck
  • Inhaler reminders improve adherence with controller treatment in primary care patients with asthma.

Inhaler reminders improve adherence with controller treatment in primary care patients with asthma.

The Journal of allergy and clinical immunology (2014-07-27)
Juliet M Foster, Tim Usherwood, Lorraine Smith, Susan M Sawyer, Wei Xuan, Cynthia S Rand, Helen K Reddel
ABSTRACT

Poor adherence contributes to uncontrolled asthma. Pragmatic adherence interventions for primary care settings are lacking. To test the effectiveness of 2 brief general practitioner (GP)-delivered interventions for improving adherence and asthma control. In a 6-month cluster randomized 2 × 2 factorial controlled trial, with GP as unit of cluster, we compared inhaler reminders and feedback (IRF) and/or personalized adherence discussions (PADs) with active usual care alone; all GPs received action plan and inhaler technique training. GPs enrolled patients prescribed combination controller inhalers, with suboptimal Asthma Control Test (ACT) scores (ACT score ≤19). Inhaler monitors recorded fluticasone propionate/salmeterol adherence (covertly for non-IRF groups) and, in IRF groups, provided twice-daily reminders for missed doses, and adherence feedback. PAD GPs received communication training regarding adherence. Outcomes collected every 2 months included ACT scores (primary outcome) and severe exacerbations. Intention-to-treat mixed-model analysis incorporated cluster effect and repeated measures. A total of 43 GPs enrolled 143 patients with moderate-severe asthma (mean age, 40.3 ± 15.2 years; ACT score, 14.6 ± 3.8; fluticasone propionate dose, 718 ± 470 μg). Over 6 months, adherence was significantly higher in the IRF group than in non-IRF groups (73% ± 26% vs 46% ± 28% of prescribed daily doses; P < .0001), but not between PAD and non-PAD groups. Asthma control improved overall (mean change in ACT score, 4.5 ± 4.9; P < .0001), with no significant difference among groups (P = .14). Severe exacerbations were experienced by 11% of the patients in IRF groups and 28% of the patients in non-IRF groups (P = .013; after adjustment for exacerbation history; P = .06). Inhaler reminders offer an effective strategy for improving adherence in primary care compared with a behavioral intervention or usual care, although this may not be reflected in differences in day-to-day asthma control.

MATERIALS
Product Number
Brand
Product Description

Salbutamol sulfate, European Pharmacopoeia (EP) Reference Standard
Supelco
Albuterol sulfate, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Fluticasone propionate, United States Pharmacopeia (USP) Reference Standard
Fluticasone propionate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Salbutamol
Sigma-Aldrich
Salbutamol hemisulfate salt, ≥98%
Salbutamol, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Fluticasone propionate, ≥98% (HPLC), powder
Supelco
Salbutamol, VETRANAL®, analytical standard